Abstract: The present invention relates to the ophthalmic composition comprising from about 0.03% to about 2% by weight of cyclosporine, from about 0.05% to about 5% by weight of tamarind seed polysaccharide and a pharmaceutically acceptable carrier. Further the invention relates to the process for preparation of ophthalmic compositions and its use for the treatment of dry eye.

Abstract: Compositions are disclosed herein comprising poly alpha-1,3-glucan or poly alpha-1,3-1,6-glucan polymer having an open-cell pore structure with an average pore size of about 100 nm to about 3000 nm in diameter. Such polymers have enhanced aqueous liquid absorption capacity, and can be comprised in various products having aqueous liquid absorption function. Methods of preparing glucan polymers of the compositions provided herein are also disclosed.

Abstract: Compositions and methods are for combating inflammatory disease and particularly for use in feed or food compositions for preventing, reducing and/or treating inflammatory disorders, diseases, or discomforts. The compositions include at least one specific pectin.

Abstract: The application describes compositions that include maltosyl-isomalto-oligosaccharides with a desirable mass average molecular weight distribution. In some cases, the compositions can contain at least 3% mannitol.

Abstract: Disclosed is a low molecular weight (1000-5000 daltons) chondroitin sulfate (CS) produced by chemical sulfation of a non-sulfated chondroitin backbone (K4 capsular polysaccharide) obtained with biotechnology techniques. The CS described is substantially monosulfated, mainly at the 6-position, with very little sulfation at the 4-position, and with a mono/disulfated disaccharide ratio and charge density similar to those of natural CS. Said biotechnological chondroitin sulfate (CS) is useful in the treatment and prevention of osteoarthritis and in acute and chronic inflammatory processes.

Abstract: Compositions are disclosed herein comprising at least one dextran ether compound that comprises uncharged, anionic, and/or cationic organic groups. The degree of substitution of one or more dextran ether compounds is about 0.0025 to about 3.0. Dextran from which the disclosed ether compounds can be derived can have a weight-average molecular weight of about 50-200 million Daltons and/or a z-average radius of gyration of about 200-280 nm. Also disclosed are methods of producing dextran ether compounds, as well as methods of using these ether compounds in various applications.

Abstract: A method for producing membrane polysaccharides from an organism selected from micro-organisms, unicellular organisms and filamentous fungi, the method including at least one step of extracting the membrane polysaccharides as well as a smaller-scale extraction of the soluble proteins, by mechanical treatment of the organism in a ball mill or by physical treatment of the organism by means of ultrasounds.

Abstract: Methods and hydrogels for preventing or reducing cellular adhesion and protein adsorption to a tissue (e.g. cardiac tissue) are disclosed. The hydrogels generally include at least two component polymers, a first polymer including an aminooxy group and a second polymer including a reactive oxo group, that are cross-linked by oxime bonds. The hydrogels are suitable for binding to and coating a tissue or cell. The hydrogels operate to reduce cellular adhesions and protein adsorption to the tissue or cell.

Abstract: A gas permeable ophthalmic lens material comprises a tetraethoxysilane and an ionic silane. The ionic silane comprises positive charges and negative charges. The lens made therefrom thus comprises positive and negative charges, thus the gas permeable ophthalmic lens is hydrophilic, and prevents adhesion of bacteria in allowing the surface of the human eye to breath. A gas permeable ophthalmic lens made of the gas permeable ophthalmic lens material is also provided.

Abstract: A method for manufacturing a pharmaceutical composition for reducing the frequency of urination is disclosed. The pharmaceutical composition comprises (1) an analgesic agent and (2) an ?-blocker, a 5?-reductase inhibitor or both.

Abstract: The present invention relates to: a novel method for preparing an injectable cross-linked hydrogel containing hyaluronic acid, or one of the salts thereof, a hydrogel obtained according to said preparation method, and use of the hydrogel obtained according to said preparation method in the fields of aesthetics and medicine.

Abstract: The invention provides a composition containing hyaluronic acid (HA) or a pharmaceutically-acceptable salt thereof preserved with a cationic preservative and related methods. In one embodiment, the pharmaceutically-acceptable salt is sodium hyaluronate. In another embodiment, the cationic preservative includes benzalkonium chloride (BAK).

Abstract: The present invention relates to a sterile aqueous ophthalmic solution comprising N—(N-acetylcysteinyl-)chitosan or a pharmaceutically acceptable salt thereof in a carrier solution, wherein the N—(N-acetylcysteinyl-)chitosan has a content of free thiol groups in an amount of from 80 ?mol/g polymer to 280 ?mol/g polymer, for use in the treatment of corneal wounds.

Abstract: The present invention provides compositions, systems, kits, and methods for preparation prior to a colonoscopy or other gastrointestinal procedure. In particular, the present invention provides a colon lavage system comprising an aqueous portion and a solid portion.

Abstract: Administration of low molecular weight (10,000-20,000 Daltons, or lower) pectins, particularly modified citrus pectins (MCP), like PectaSol-C reduces galectins-3 levels in vivo. Reduction of galectin-3 levels by MCP inhibits inflammation, inhibits fibrosis formation in organs and tissues, and inhibits cancer formation, progression, transformation and metastases. The reduction in circulating, serum and cellular galectin-3, inherently resulting from the administration of MCP, provides benefit over a spectrum of biological conditions, as evidenced by in vivo trials.

Abstract: Methods of encapsulating microorganisms, or components thereof, for targeted enteric delivery to an animal host have been developed. In particular, the encapsulation provides a prolonged survival, extended retention and a pH-sensitive release of the encapsulated microorganisms or antigenic components thereof at targeted sites within the gastrointestinal tract. The formulations are useful for diagnostic, therapeutic and prophylactic purposes and can alter a host's microbial composition associated with a condition or a disease state.

Abstract: A low-molecular-weight fucosylated glycosaminoglycan (aTFG) containing 2,5-anhydrated talose, alditol, glycosylamine or N-substituted glycosylamine monosaccharide composition thereof, preparation method thereof, pharmaceutical compositions containing the aTFG, and use thereof for preventing and/or treating thrombotic diseases are provided. The aTFG has potent anticoagulant activity targeting at intrinsic coagulation factor Xase, and inhibiting thrombogenesis, and therefore can be used as drugs for preventing and/or treating cardiovascular and cerebrovascular diseases.

Abstract: The present disclosure provides an elastomeric material for the delivery of an ophthalmic agent to the eye of a subject and methods of using such material.

Abstract: A troche comprising at least 5 mg hyaluronan, wherein the troche is adherent, and wherein hyaluronan is released from the troche, is used to treat mucositis, including stomatitis, vestibulitis, aphthous ulcerations, lichen planus and Behcet's syndrome. A method for treating or preventing mucositis in a patient is provided, comprising applying to a mucosal surface or a tooth or orthodontic brace of a patient in need thereof an adhering troche comprising at least 5 mg hyaluronan.

Abstract: The invention proposes a polymer solution for visco-supplementation. The polymer solution contains at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water, whereby the polymer solution is clear to the eye. Moreover, the invention describes a method for sterilization of the polymer solution. This method is characterized in that a mixture of at least one at least partially water-soluble polysaccharide or polysaccharide derivative, one water-soluble alkali salt or alkaline earth salt of polystyrene sulfonic acid, and water is mixed with at least 0.5 wt. % ß-propiolactone, and in that the polymer solution is stored at room temperature for at least 24 hours.

Abstract: The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.

Abstract: A method of extracting lentinan from lentinan containing mushrooms comprising the step of contacting the mushrooms with an ionic liquid so as to obtain a lentinan rich ionic liquid solution.

Abstract: Provided are compositions useful as dietary supplements for the relief of unstable gastrointestinal symptoms such as constipation and diarrhea and methods of using same. The compositions consist essentially of the extract of the fruits of Coffea arabica, in combination with other materials recognized by those skilled in the art as being useful secondary ingredients in a composition for oral administration. The secondary ingredients do not affect the basic properties conferred by the presence of the extract of Coffea arabica, The extract of Coffea arabica is present in compositions according to the disclosure in relatively high amounts, and the compositions are devoid of any dietary fiber other than that incidental in the extracts, and are free from any added alginic acids or their salts. Methods according to the disclosure are described, which involve daily oral administration of the compositions described prior to mealtime.

Abstract: Injectable compositions and methods for treating an injured tendon in an animal or human are disclosed herein. The injectable compositions include an effective amount of a carbohydrate to increase osteotendinous hydration and lubrication.

Abstract: The present invention provides a method of preparing an isolated oligosaccharide or glycolipid by preparing the oligosaccharide or glycolipid having a hydrophobic group, such as a perfluorinated alkyl or a fatty acid, and separating the oligosaccharide or glycolipid using a solid-phase extraction cartridge.

Abstract: Aspects of the invention provide compositions for use in the treatment galectin-dependent diseases. In particular, compositions comprising a selectively depolymerized, branched galactoarabino-rhamnogalacturonate whose backbone is predominantly comprised of 1,4-linked galacturonic acid (GalA) moieties, with a lesser backbone composition of alternating 1,4-linked GalA and 1,2-linked rhamnose (Rha), which in-turn is linked to any number of side chains, including predominantly 1,4-b-D-galactose (Gal) and 1,5-a-L-arabinose (Ara) residues.

Abstract: Provided is a chondroitin sulfate derivative having a cross-linked structure through a group in a polyvalent amine. Also provided is a composition containing the chondroitin sulfate derivative. Also provided are an agent and method for the treatment of an eye disease, the agent and method having a therapeutic effect on a corneal epithelial disorder and/or dry eye.

Abstract: There is provided a polymer-flavonoid conjugate, or a pharmaceutically acceptable salt thereof, uses thereof, and methods of making thereof. The disclosed polymer-flavonoid conjugates may be useful in the therapeutic and/or prophylactic treatment of a joint condition in a subject.

Abstract: A dextran sulfate, or a salt thereof, has a number average molecular weight (Mn) as measured by NMR spectroscopy within an interval of 1850 and 3500 Da. The dextran sulfate, or the salt thereof, also has an average sulfate number per glucose unit within an interval of 2.5 and 3.0. Furthermore, an average sulfation of C2 position in the glucose units of the dextran sulfate, or the salt thereof, is at least 90%. The dextran sulfate has improved biological effects and/or reduced toxicity as compared to similar dextran sulfate molecules available on the market.

Abstract: Methods and compositions of the invention relate to the enhancement of specific immunotherapies in cancer treatment. In particular, aspects of the invention relate to novel approaches to boost immune function using a complex carbohydrate pharmaceutical compound alone or in combination with other targeted immunotherapy to increase the efficacy of immunotherapy of cancer.

Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.

Abstract: A computer executable method that can be stored in a memory, the method including: visually presenting on a display of a user device a history of UV dose that was calculated based on information sensed by a UV sensor in a wearable UV sensing device; visually presenting a percentile indicator on the display, the percentile indicator being indicative of a calculated percentile of the history of UV dose; and visually presenting on the display a user-adjustable UV dose threshold interface that is adapted to allow the user to interact with the user-adjustable UV dose interface and choose a user-chosen UV dose threshold quantity.

Abstract: Disclosed herein is a refined product obtained from a rice hull, which consists essentially of a type II arabinogalactan having a number average molecular weight in the range of 56 to 103 kDa. Also disclosed are a process for producing the refined product and use of the refined product for enhancing the biological activity of innate immune cells, as well as for treating allergy and cancer.

Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.

Abstract: A non-synthetic, hydrophilic, biodegradable, biocompatible polysaccharide based non-toxic anti-adhesion hydrogel barrier is disclosed herein. The barrier of the present invention is formed by constructing a unique interpenetrating, crosslinked network with a unique porosity. Furthermore, the barrier of the present invention is comprised of tunable biopolymers for controllable mechanical robustness and degradation. The barrier of the present invention effectively reduces unwanted adhesions using non-synthetic components.

Abstract: The present invention provides use of taurine in prevention and/or treatment of diseases induced by viruses of genus coronavirus and/or genus rotavirus, for example, porcine epidemic diarrhea, porcine transmissible gastroenteritis, rotavirus diarrhea and the like.

Abstract: The present invention relates to a process for preparing a crosslinked gel of at least one polysaccharide or a salt thereof, comprising at least the steps consisting in: a) providing a solution formed from an aqueous medium comprising at least said polysaccharide(s) or a salt thereof in a non-crosslinked form, at least one difunctional or multifunctional epoxide crosslinking agent chosen from butanediol diglycidyl ether, diepoxyoctane, 1,2-bis(2,3-epoxypropyl)-2,3-ethylene, and mixtures thereof, and at least one phosphate salt; b) crosslinking the solution from step a) and, where appropriate; c) recovering said crosslinked gel formed.

Abstract: Sterilization method according to which an aqueous polysaccharide solution is stored in the presence of a lactone and a buffer system for a period of at least 24 hours, and a sterile polysaccharide solution produced in this way.

Abstract: The present invention relates to polysaccharide soft tissue fillers comprising heparosan and processes for their preparation. The polysaccharide soft tissue fillers of the present invention are advantageously used in therapeutic or cosmetic applications such as for the filling of wrinkles.

Abstract: A method for modulating angiogenesis in a cancer or tumor refractory to anti-VEGF, including identifying a cancer cell as being referactory to anti-VEGF, and then contacting the cancer cell refractory to anti-VEGF with an effective amount of an agent that modulates interaction between Gal1 or a Gal1 fragment and the natural binding partner of Gal1 or the Gal1 fragment to thereby modulate angiogenesis.

Abstract: Systems and methods provide sugar alcohol to heat stressed ruminants to improve performance. During periods of high temperature or humidity, heat stressed ruminants may exhibit decreased dry matter intake, and in response, an effective amount of sugar alcohol such as sorbitol may be provided in the ruminant diet to cause performance to increase, which may include increased milk yield, improved feed efficiency or both compared to heat stressed dairy cattle without sugar alcohol in the diet.

Abstract: The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).

Abstract: Use of hyaluronic acid as the sole active ingredient for preparing compositions in particular for topical use for treating oral cavity aphthas.

Abstract: This invention provides a high molecular weight polysaccharide capable of binding to and inhibiting virus and related pharmaceutical formulations and methods of inhibiting viral infectivity and/or pathogenicity, as well as immunogenic compositions. The invention further includes methods of inhibiting the growth of cancer cells and of ameliorating a symptom of aging. Additionally, the invention provides methods of detecting and/or quantifying and/or isolating viruses.

Abstract: The present invention relates to a sterile and/or decontaminated composition for topical use, including hyaluronic acid at a concentration of greater than or equal to 0.1 wt % relative to the total weight of the composition, at least one skin wound healing agent, optionally at least one plant extract, and at least one solvent. The invention also relates to a unit including such a composition, to a method for preparing such a composition, and to the uses thereof.

Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations contain hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Abstract: Chondroitin, a metabolic intermediate of chondroitin sulphate biosynthesis in mammals and other living organisms, possesses biological properties different from those of chondroitin sulphate, and can be advantageously used for applications in the pharmaceutical, nutraceutical, cosmeceutical and medical device fields. Chondroitin has biostimulating, anti-inflammatory and anti-microbial activity and can be used in the treatment of osteoarthritis, eye disorders, interstitial cystitis, lung disorders, inflammatory disorders in general, oncological disorders, peritoneal dialysis, tissue biorevitalisation and wound repair, as a skin filler, and as bioresorbable scaffolds.

Abstract: The present invention provides oral solutions containing sotalol hydrochloride which advantageously avoid swallowing while providing with improved stability. The present invention also relates to methods of using the oral solutions for treatment of diseases and disorders, such as delay in reoccurrence of atrial fibrillation/atrial flutter and/or ventricular arrhythmias.

Abstract: An object of the present invention is to provide an antiviral fiber assembly in which an antiviral agent is retained with chemical stability over a long period of time, and which is gentle to the human body. A further object of the present invention is to provide a fiber assembly with cellulose sulfate that can exhibit sufficient antiviral activity over a long period of time. Further, another object of the present invention is to provide a textile product obtained using such a fiber assembly. The present invention provides a fiber assembly with cellulose sulfate, wherein the hyaluronidase inhibitory activity is 50% or higher; and a process for producing a fiber assembly with cellulose sulfate, including treating a fiber assembly with an aqueous cellulose sulfate solution and drying, then treating the same with a pH buffer solution and drying.

Abstract: Disclosed herein is an extract obtainable from Trigonella foenum-graecum. In particular, the extract is obtainable by a process comprising the steps of preparing a mixture of a plant material obtained from Trigonella foenum-graecum and liquid, incubating said mixture for at least 3 hours, heating of said mixture, and recovering a liquid extract from mixture. The extract is useful in the manufacture of various types of compositions, such as pharmaceutical compositions, disinfectant or preservation agents. The pharmaceutical may be used for the treatment or prevention of an inflammatory disease or an infectious condition.